Barclays Maintains Equal-Weight on Pfizer, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Pfizer (NYSE:PFE) and raises the price target from $30 to $32.
July 31, 2024 | 7:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Carter Gould maintains an Equal-Weight rating on Pfizer and raises the price target from $30 to $32.
The raised price target from $30 to $32 by Barclays suggests a positive outlook on Pfizer's stock, which could lead to a short-term price increase. However, the Equal-Weight rating indicates a neutral stance, balancing the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100